ALEXANDER SUSAN H, EVP Chief Legal Officer, has demonstrated a consistent pattern of selling activity in Biogen Inc. (BIIB) shares, as reflected in SEC Form 4 filings. Over the course of 25 reported transactions, Alexander has exclusively sold shares, with no recorded purchases. The total value of these sales amounts to $1,911,724.10, indicating a significant divestment of holdings in the company. Notably, the transactions span multiple dates, with notable sales occurring on February 6, 2026, totaling $304,586.52, $187,298.58, and $213,049.62, respectively. Earlier transactions include sales on February 16, 2024, valued at $171,101.48 and $362,796.48, as well as February 9, 2024, at $226,039.24. These sales suggest a deliberate reduction in Alexander’s stake in Biogen over time.
The absence of any buying activity in the data underscores a clear selling bias. While the filings do not provide context for the transactions, the consistent pattern of sales aligns with a strategy of reducing equity exposure in Biogen. The transactions are spread across multiple dates, indicating a measured approach rather than a single bulk sale. As of the most recent filings, Alexander has not engaged in any new buying or selling activity, leaving the current status of her holdings in Biogen unchanged. This data provides a transparent view of her trading behavior, reflecting a focus on divesting shares in the company.
AI-assisted summary